Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Springfield, MA
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Springfield, MA
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Detroit, MI
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Garden City, NY
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Garden City, NY
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Bellaire, TX
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Bellaire, TX
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Research Site
mi
from
Cordoba,
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Research Site
mi
from
Cordoba,
Click here to add this to my saved trials
Quantitative MR Biomarkers for Sarcoma Treatment
Quantitative MR Biomarkers for Sarcoma Treatment
Status: Enrolling
Updated:  12/2/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Quantitative MR Biomarkers for Sarcoma Treatment
Quantitative MR Biomarkers for Sarcoma Treatment
Status: Enrolling
Updated: 12/2/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Scleroderma ARFI Imaging of the Skin
Acoustic Radiation Force Impulse/Shear Wave Velocity Imaging of the Skin in Scleroderma and Other Rheumatologic Diseases
Status: Enrolling
Updated:  12/7/2015
University of Michigan Hospital
mi
from
Ann Arbor, MI
Scleroderma ARFI Imaging of the Skin
Acoustic Radiation Force Impulse/Shear Wave Velocity Imaging of the Skin in Scleroderma and Other Rheumatologic Diseases
Status: Enrolling
Updated: 12/7/2015
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)
Nutritional Effect of an Oral Supplement Enriched in Arginine, Glutamine and Leucine Metabolite B-Hydroxy B-Methylbutyrate
Status: Enrolling
Updated:  12/14/2015
Central Arkansas Veterans Healthcare System
mi
from
Little Rock, AR
Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)
Nutritional Effect of an Oral Supplement Enriched in Arginine, Glutamine and Leucine Metabolite B-Hydroxy B-Methylbutyrate
Status: Enrolling
Updated: 12/14/2015
Central Arkansas Veterans Healthcare System
mi
from
Little Rock, AR
Click here to add this to my saved trials
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
Study of a Bradykinin Receptor Blocker in Angiotensin Converting Enzyme Inhibitor-Associated Angioedema
Status: Enrolling
Updated:  12/16/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
Study of a Bradykinin Receptor Blocker in Angiotensin Converting Enzyme Inhibitor-Associated Angioedema
Status: Enrolling
Updated: 12/16/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.
Status: Enrolling
Updated:  12/17/2015
Johns Hopkins Arthritis Center
mi
from
Baltimore, MD
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.
Status: Enrolling
Updated: 12/17/2015
Johns Hopkins Arthritis Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated:  12/31/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated: 12/31/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated:  12/31/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated: 12/31/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated:  12/31/2015
Walter Reed National Military Medical Center (WRNMMC)
mi
from
Bethesda, MD
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated: 12/31/2015
Walter Reed National Military Medical Center (WRNMMC)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) Coordinating Center
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury (Coordinating Center Protocol)
Status: Enrolling
Updated:  1/2/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) Coordinating Center
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury (Coordinating Center Protocol)
Status: Enrolling
Updated: 1/2/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis
Status: Enrolling
Updated:  1/7/2016
North Shore LIJ Medical Center
mi
from
Great Neck, NY
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis
Status: Enrolling
Updated: 1/7/2016
North Shore LIJ Medical Center
mi
from
Great Neck, NY
Click here to add this to my saved trials
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis
Status: Enrolling
Updated:  1/7/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis
Status: Enrolling
Updated: 1/7/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hyperbaric Oxygen in Lower Leg Trauma
Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.
Status: Enrolling
Updated:  1/13/2016
John Muir Clinical Research Center
mi
from
Concord, CA
Hyperbaric Oxygen in Lower Leg Trauma
Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.
Status: Enrolling
Updated: 1/13/2016
John Muir Clinical Research Center
mi
from
Concord, CA
Click here to add this to my saved trials
Hyperbaric Oxygen in Lower Leg Trauma
Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.
Status: Enrolling
Updated:  1/13/2016
Royal Hobart Hospital
mi
from
Hobart,
Hyperbaric Oxygen in Lower Leg Trauma
Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.
Status: Enrolling
Updated: 1/13/2016
Royal Hobart Hospital
mi
from
Hobart,
Click here to add this to my saved trials
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Status: Enrolling
Updated:  1/20/2016
Houston Medical Center Building
mi
from
Houston, TX
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Status: Enrolling
Updated: 1/20/2016
Houston Medical Center Building
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Status: Enrolling
Updated:  1/21/2016
NYU Medical Center
mi
from
New York, NY
Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Status: Enrolling
Updated: 1/21/2016
NYU Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial on Wheeled Mobility for Preventing Pressure Ulcers
RCT on Wheeled Mobility for Preventing Pressure Ulcers
Status: Enrolling
Updated:  1/25/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Trial on Wheeled Mobility for Preventing Pressure Ulcers
RCT on Wheeled Mobility for Preventing Pressure Ulcers
Status: Enrolling
Updated: 1/25/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
La Mesa, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
La Mesa, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Oceanside, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Oxnard, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Oxnard, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Pasadena, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Santa Ana, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Torrance, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Columbus, GA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Columbus, GA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Savannah, GA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Springfield, IL
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Detroit, MI
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Butte, MT
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Butte, MT
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Somers Point, NJ
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Akron, OH
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Birmingham, AL
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Granada Hills, CA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Granada Hills, CA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
San Diego, CA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
San Diego, CA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Walnut Creek, CA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Shreveport, LA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Chevy Chase, MD
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Boston, MA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
Plymouth, MN
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
Plymouth, MN
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
mi
from
St Louis, MO
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials